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ABSTRACT
Background
Cancer occurs in approximately 1:1000 pregnancies. When chemotherapy cannot be delayed until postpartum,
beginning chemotherapy is based on presumed safety after organogenesis is completed during the first trimester. The
safest gestational age to start chemotherapy after the first trimester is unknown.
Patients and Methods
In an observational cohort of pregnant women diagnosed and treated for cancer at multiple centers, pregnancy
outcomes for the mother, and clinical outcomes for the neonate were analyzed according to the gestational age in
weeks of pregnancy at first chemotherapy cycle. Outcomes including birth weight, fetal growth restriction, congenital
malformations, and perinatal complications for mother and infant were analyzed according to gestational age of
chemotherapy initiation. Neonatal growth, general health and developmental assessment were provided annually by
each child’s pediatrician. For each outcome, cut-point of gestational age at first chemotherapy after 12 weeks was
determined with odds ratios (OR).
Results
Data from 225 women (231 fetuses) were analyzed. Initiating chemotherapy before 15 weeks GA significantly increased
risk for intrauterine growth restriction (OR=3.0), before 16.6weeks GA increased risk for congenital anomalies
(OR=3.9), and before 18 weeks GA increased risk for spontaneous preterm birth (OR=2.3). Maternal and neonatal
complications during pregnancy or follow up were not statistically different based on GA when chemotherapy began.
Conclusions
During the second trimester, the ideal time to start chemotherapy should consider maternal benefit versus neonatal
risk. With a history of spontaneous preterm birth in a prior pregnancy, delaying chemotherapy until 18 weeks may
decrease recurrent preterm birth, if not detrimental to the mother. The risk for fetal growth restriction increased with
chemotherapy initiation before 15 weeks, and for congenital malformations before 17 weeks.
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INTRODUCTION
Cancer is uncommonly diagnosed during pregnancy, but the incidence is increasing due to delayed childbearing. The
most common cancers affecting reproductive age women are breast, cervical, thyroid, melanoma and Hodgkin’s
lymphoma [1]. Termination of pregnancy has not been shown to improve patient survival [2-5]. Except for indolent
chronic lymphomas, early-stage Hodgkin’s Lymphoma, or patients diagnosed late in the third trimester, delaying
chemotherapy until after delivery may compromise maternal survival. Case reports or retrospective series limited to
infant condition at birth comprise the majority of the current literature on chemotherapy use in pregnancy [6-13]. This
spurred the creation of the Cancer and Pregnancy Registry Cohort Study to prospectively follow pregnant women
diagnosed with cancer at multiple centers and note the outcomes of the children long term. This cohort includes women
treated internationally. It has become the de facto standard that chemotherapy is avoided during the first trimester, when
fetal organogenesis occurs and anomalies have been reported with first trimester exposures [ 6]. No previous study has
compared the neonatal consequences, if any, between second and third trimester exposure. The ideal time to begin
chemotherapy after organogenesis is in fact not known. In this study, only looking at chemotherapy exposures after 12
weeks gestational age (GA), we evaluate fetal and maternal outcomes of initiating chemotherapy during the second versus
third trimester of pregnancy. Our primary objective is to determine how the gestational age at which chemotherapy is
started may affect neonatal or pregnancy complications.

MATERIAL AND METHODS
Design, Setting, and Participants, this is an observational cohort study of pregnant women enrolled in the Cancer and
Pregnancy Registry study (on ClinicalTrials.GovNCT02749474). Inclusion criteria: the diagnosis of cancer during
pregnancy, i.e. for any woman between the date of their last menstrual period and the end of pregnancy either by
miscarriage or delivery. Women who were diagnosed postpartum were excluded. All registered patients diagnosed with
primary cancer between January 1, 1994, and January 31, 2016, were eligible for inclusion, independent of outcome of the
pregnancy, cancer type or treatment. Creation of this observational cohort was approved by the Institutional Review Board
of Cooper Medical School at Rowan University, and written informed consent was obtained from patients before
prospective inclusion at the time of diagnosis in pregnancy. Patient country of treatment does not affect enrollment.
Enrollment is ongoing. Pregnancy and neonatal outcomes were analyzed according to GA at first chemotherapy treatment.
Outcomes include GA at birth, birthweight and incidence of intrauterine growth restriction (IUGR) defined as birthweight
percentile <10%, incidence of spontaneous preterm birth <35weeks, congenital anomalies, neonatal neutropenia based on
complete blood count and differential collected on first day of life, perinatal complications, and long-term medical and
behavioral diagnoses for the infant. . For birthweight percentile, the customized GROW centile calculator (version 8.0.1
(2018) from www.gestation.net was used to calculate a birth weight percentile [14]. Maternal complications include
gestational diabetes, placenta previa or abruption, postpartum hemorrhage, and depression during pregnancy or
postpartum. Spontaneous preterm delivery is counted after excluding elective iatrogenic preterm births. Neonatal
complications include respiratory distress, tachypnea, apnea or anemia of prematurity, hyperbilirubinemia, sepsis or
rashes. Complications related to birth defects, such as a urinary tract infection due to vesicoureteral reflux from urologic
anomalies are not additionally counted in this category. Height and weight percentiles, general developmental assessment,
and treatment for medical conditions are assessed by each child’s pediatrician annually. To monitor the development of
children exposed to chemotherapy in utero standardized motor, language, and cognitive assessments were performed
using the Bayley III, Wechsler Individual Achievement Test-Third Edition WIAT or Wechsler Preschool and Primary Scale
of Intelligence (WHIPPSI) at appropriate ages. Parents were asked to assess childhood clinical behavioral using the
Complete Behavioral Checklist (CBCL). Major birth defects were defined according to the Metropolitan Atlanta Congenital
Defects Program code modifications developed by the Division of Birth Defects and Developmental Disabilities, U.S.
Department of Health and Human Services. Statistical comparisons were made for primary outcomes based on GA when
treatment began. For each outcome, GA at first chemotherapy treatment was analyzed for a significant cut-point using
recursive partitioning. Odds ratios with 95% confidence intervals were calculated using logistic regression. Gestational
age at birth was used to adjust effects on outcomes as appropriate. All analyses were done using SAS v9•4 (SAS Institute,
Cary, NC).

RESULTS
Descriptive demographics are described here, followed by tables for pregnancy and neonatal outcomes. An international
cohort of 225 women with cancer and 231 fetuses (including 6 sets of twins) who were treated with chemotherapy after 12
weeks of pregnancy were identified from the Cancer and Pregnancy Registry cohort. Cancer types included breast (159);
Hodgkin’s disease (24); non-Hodgkin’s lymphoma (12); ovarian (11); colorectal (7); cervical (5); acute leukemia (2); and
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choriocarcinoma (1), sarcoma (1), chronic leukemia and bladder (1), bone (1), and pancreatic (1).The most common
chemotherapy regimens in pregnancy were doxorubicin/cyclophosphamide;5-fluouracil/doxorubicin/cyclophosphamide:
and doxorubicin/bleomycin/vinblastine/dacarbazine. Mean fetal GA at cancer diagnosis for the entire cohort regardless of
GA at treatment initiation was 20•7 (SD 5.4) weeks, and the mean number of chemotherapy cycles was 4•3 (SD 2.1). Mean
GA at delivery was 36•4 (SD 2•6) weeks; mean birth weight was 2588 (SD 636) grams. Mean GA at first chemotherapy
treatment was 21•2 weeks (SD 5•5). Mean stage at diagnosis was II. In Table 1, outcomes are compared by gestational age
at which chemotherapy was started for the following outcomes: GA at delivery, mean neonatal birthweight, incidence of
spontaneous preterm birth, and intrauterine growth restriction (IUGR).
Mean Gestational Age at Delivery, Mean Birth Weight (in weeks) Gestational age at delivery
Trimester of Diagnosis (weeks)
Mean gestational age at
Delivery (weeks)
N Pregnancies
Mean birth weight (grams)
N Infants

12-24

≥ 25

Total

36.5+2.66

36.6+2.26

36.4+2.6

166
2552+645
*172

59
2789+596
59

225
2588+636
231

p
0.95
.03

*twins Spontaneous Preterm Birth
p

12-24
32
166
19.2

≥ 25
9
59
15.2

Total
41
225
18.2

0.49

N Pregnancies

18
146

5
50

Preterm birth <35 weeks (%)

12.3%

10%

23
225-29iatrogenic preterm
birth <35w=196
11.7%

0.66

Spontaneous Preterm birth <37weeks
N Pregnancies
Preterm birth<37weeks (%)
Spontaneous Preterm birth <35weeks

Incidence Intrauterine Growth Restriction - IUGR=Birth weight <10% for gestational age at birth
IUGR (Birth percentile<10%)
N Infants
IUGR (%)

12-24
42
139
30%

≥ 25
11
47
23.4%

Total
53
186
28.5%

p

0.37

Table1: Mean Gestational Age at Delivery and Mean Birth Weight, Non-Iatrogenic Premature Birth Prior to 37 Gestational Weeks,
and Intrauterine Growth Restriction according to Gestational Age at First Cycle of Chemotherapy.

There was a significantly lower mean birthweight in the group starting chemotherapy between 12-24 weeks compared to
the group beginning treatment after 25 weeks, 2552 +645g vs 2789 +596g, p=0.03. There was no significant difference in
spontaneous preterm deliveries prior to 37weeks when chemotherapy was started between 12-24 weeks compared to after
25.0 weeks, 19.2% versus 15.2 %, p=0.49. In 82 cases, an elective preterm birth iatrogenically occurred in order to resume
cancer therapy without waiting for spontaneous labor. The majority of these occurred between 35 and 37weeks. After
excluding 29 iatrogenic (elective) preterm deliveries (< 35 weeks), the incidence of early spontaneous preterm birth was
11.7%, occurring in 23/196 pregnancies. There remained no significant difference in the incidence of spontaneous preterm
birth between the group starting chemotherapy 12-24 weeks, and those starting after 25 weeks gestational age, p=.0.66
For 45 deliveries, despite having the gestational age, birthweight and gender missing demographics for the mother would
not allow a calculation of a birthweight percentile. For the remaining 186 infants for which a birthweight percentile could
be calculated using gestation.net, the overall incidence of IUGR (birth percentile <10%) was 53/186 (28.5%). There was no
significant difference in the incidence of IUGR between starting chemotherapy 12-24 weeks versus after 25 weeks, 30%
vs. 23.4%, p=0.28.
Seven major birth defects (3•1%) were reported for the cohort at birth. The purpose of longitudinal follow up for this
cohort is to detect any anomalies diagnosed up until 5 years of age. In fact, 12 additional children were diagnosed with a
birth defect between 1 and 22 months of age. In Table 2, the incidence of congenital anomalies diagnosed in early
childhood is compared between the 2 treatment groups.
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Incidence of Major Birth Defects
12-24
18
10.5%
172

Birth Defect N
Birth Defect (%)
N Infants

≥ 25
1
1.7%
59

Total
19
8.2%
231

p
0.05

Incidence of Neonatal Neutropenia at Birth
Neutropenia N
Neutropenia (%)
Preterm birth?

12-14*
4
23.3%
Yes, 34.9- 36.6wks

Days Between Chemotherapy & Delivery

21-98

N Infants

172

≥ 25
0
0%

Total
4
1.7%

59

231

p
0.57

Incidence of Pregnancy Complications (Maternal)*
Pregnancy Complications N
Pregnancy Complications (%)
N Pregnancies

12-24
40
24%
166

≥ 25
9
15.3%
59

Total
49
21.6%
225

p
0.20

*Excluding Spontaneous Preterm birth

Incidence of Perinatal Complications (Neonates)*
12-14
30

≥ 25
13

Total
43

p

Neonatal Complications N
Neonatal Complications (%)

17.4%

22.0%

18.6%

0.44

N Infants

172

59

231

*Excluding IUGR and birth defects

Table 2: Incidence of Major Birth Defects, Neonatal Neutropenia at Birth and Pregnancy and Perinatal Complications for Maternal
and Neonatal by Gestational Age at Initiation of Chemotherapy (in weeks)

A total of 19 anomalies (8.2%) were diagnosed in this cohort by age 2 years. There was a significant difference in the
incidence of birth defects when treatment began between 12-24 weeks GA when compared with >25, p=•05. One of these
occurred in a family known to carry the autosomal dominant mutation for the same defect (father of child affected). Birth
defects are further detailed in Supplemental Table 1, including the type of anomaly, GA at first treatment, treatment
required, and neonatal age and status at latest follow up. Most of the birth defects were not life-threatening, aside from a
single case of spina bifida, which likely occurred prior to initial chemotherapy exposure at 14•7 weeks GA.
Also in Table 2, the incidence of neonatal neutropenia was compared between groups and was not found to be significantly
different when chemotherapy began at 12-24 weeks GA vs >25 weeks GA, p=•57 (Table 2). All infants born with
neutropenia were preterm. Other neonatal complications were not significantly related to GA at first chemotherapy cycle,
p=0.44. There was no significant difference in the incidence of maternal complications at delivery when chemotherapy
began at 12-24 weeks GA vs >21-24 weeks GA, p=•20. Maternal and neonatal complications during pregnancy, delivery, or
newborn period are described in Supplemental Table 2. The incidence of postnatal pediatric medical conditions;
developmental, language and motor delays; and behavioral issues are compared in Table 3. These were not significantly
related to the GA at first chemotherapy treatment. The types of maternal and neonatal complications during pregnancy,
delivery, or newborn period are further described in detail in Supplemental Table 2. For each primary outcome, GA at
first chemotherapy cycle was analyzed for a significant GA cut-point using recursive partitioning. The significant GA cutpoint for birth defects was <17 weeks at first chemotherapy exposure.
This corresponded to a 3•9-fold increased risk of birth defects, OR =3•9 (95% CI 1•43, 10•9) (p=•008), if chemotherapy
began at <17 weeks GA.

Proclins Gynecol Obstet

4/ 15

Incidence of Pediatric Medical Conditions
Pediatric Medical
ConditionsN
Pediatric Medical
Conditions (%)
N Infants
Developmental/
Language or Motor
DelayN
Developmental/
Language or Motor Delay
(%)
N Infants

12-24

≥ 25

Total

56

21

77

35.9%

43.8%

37.8%

156

48

204

13

8

21

8.3%

16.7%

10.3%

156

48

204

p

0.39

0.11

Incidence of Behavioral Issues
Behavioral Issues N
Behavioral Issues (%)
N Infants

12-24
5
3.2%
156

≥ 25
1
2.1%
48

Total
6
2.9%
204

p
1.0

Table 3: Incidence of Pediatric Complications after Birth including medical conditions, language and motor delays, or behavioral
issues by Trimester at Initiation of Chemotherapy (in weeks)

The significant cut-point for spontaneous preterm birth was 18 weeks GA, and 15 weeks GA for intrauterine fetal growth
restriction. Odds ratios were: congenital anomalies, 16.6 weeks GA, OR=3.9 (95% CI 1•4-10•9), p=•008;
PPROM/spontaneous preterm birth 18 weeks GA, OR=2•3 (95% CI 1•04, 4•86), p= •04; intrauterine growth restriction 15
weeks GA, OR=2•99 (95% CI 1•04, 8•6), p=•043.

DISCUSSION
As cancer occurs in only 1:1000 pregnancies, creation of an international cohort study of pregnant women diagnosed with
cancer was warranted. Oncologists and obstetricians require long term follow up on mothers and children to best counsel
newly diagnosed patients on the safest agents to use and safest time to begin in pregnancy, taking into account how long a
delay can be tolerated by the mother. Multidisciplinary treatment of such patients requires the following questions to be
asked:
1) After the first trimester of pregnancy is completed is any additional delay warranted to limit overall fetal exposure to
chemotherapy if it does not compromise maternal prognosis?
2) Does it make a difference to the fetus to be exposed earlier in pregnancy when compared with a later GA? To date,
there are no studies that identify the ideal time to begin chemotherapy after a diagnosis of cancer during pregnancy. In
this observational cohort study, we analyzed pregnancy outcomes for mothers and neonates, as well as long-term neonatal
health, after initial chemotherapy exposures began as early as 12 weeks GA and compared results with beginning
chemotherapy at a later GA.
The placenta grows along with the fetus, weighing about one-sixth as much as the fetus at birth. Starting chemotherapy
earlier in pregnancy may result in a lower birthweight due to decreased placental growth as an early effect of
chemotherapy on placental development. Zemlickis reported IUGR as a consequence of chemotherapy exposure in utero
in 1992 [15]. Intrauterine growth restriction, defined as birth percentile weight < 10%, was found in 20.3% of infants in
this cohort, with no significant difference between starting chemotherapy between 12-24 weeks compared to after
25weeks. Using recursive partitioning, fetal growth restriction increased significantly when treatment began prior to 15
weeks GA. The intervillous space of the placenta originates as lacunae within the syncytiotrophoblast which anastomose
with maternal capillaries filling with maternal blood at about 10 weeks’ gestation. Early villous sprouting is initiated by
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cells in regions of cytotrophoblasts and villous stroma with high proliferative activity. The number of cytotrophoblasts
increases roughly 10-fold between the 13th and 15th week and term. Cytotrophoblast cells are recruited into
syncytiotrophoblasts, which create attenuated protrusions called syncytial sprouts subsequently acquiring a vascularized
stroma to become mesenchymal villi. Starting in the 9th week, tertiary stem villi lengthen by forming terminal
mesenchymal villi, increasing the surface area available for transplacental exchange. These terminal extensions reach their
maximum length in the 16th week [16]. In cases of fetal growth restriction, the placenta histologically exhibits
compromised growth of villous trees, a smaller intervillous space, and a lower diffusive conductance and decreased total
volumes and surfaces solely attributable to reduce linear growth of villi and capillaries [17, 18]. Chemotherapy exposure
prior to achieving a maximum number of cytotrophoblasts or the villi achieving maximum length may result in deleterious
effects on fetal growth. Maternal smoking, hypertension, diabetes, medications, stress, and the underlying cancer can
impact fetal growth potential. A limitation of this study is the lack of consistent maternal smoking histories during
pregnancy.
There were no significant differences in neutropenia or other neonatal complications. With longer neonatal follow up, no
difference in medical conditions, developmental, language or motor delays, nor behavioral issues were identified
according to GA at the initiation of chemotherapy.
Three percent of neonates in the general population are born with major congenital anomalies [19, 20]. Additional
anomalies can be detected after birth; the incidence reaches 6% by 2 years and 8% by 5 years [20]. Current literature
reports no increased risk of anomalies associated with second- or third-trimester use of cytotoxic agents [6, 7, 10, 17, 2124]. Most cases describing chemotherapy use in pregnancy report the status of the neonate at birth, a few months or to
one year of age. In this cohort, 7 infants were diagnosed with congenital anomalies at birth (3%). Twelve anomalies were
diagnosed between 1 and 27 months of age for a total of 19 major anomalies among 232 infants (8•2%). Our higher rate
when compared with other publications after chemotherapy use during pregnancy is likely due to a longer follow up and
inclusion of congenital anomalies diagnosed at later ages. Our cohort data show a slightly higher rates of congenital
anomalies when compared with the anticipated rates seen in the general population by age 2 years, (7•3%), but within the
general population range of 8•2% by age 5 years. Using recursive partitioning, the delay of chemotherapy until 16.6weeks
may significantly decrease the incidence of birth defects. This decision must be balanced against the maternal risks of
delaying treatment. For each GA week that chemotherapy was delayed, incidence of birth defects decreased by 12% (data
not shown). As shown in Supplemental Table 1, no birth defects were life threatening, and few of the children required
long-term therapy. Parents should be informed of the anomalies that may be diagnosed if chemotherapy cannot be safely
delayed until 16.6 weeks GA without compromising maternal health.
Aviles and colleagues reported detailed follow-up of 84 children exposed in-utero to chemotherapy in 2001 [21].
Neurological, intellectual, and visual-motor assessments performed by blinded physicians were no different for exposed
children when compared with siblings and non-related controls. Amant et al. reported a on the development and cognitive
performance of 70 children exposed to cancer treatment in utero. Children who exhibited delays were concentrated in the
group delivered preterm [22, 24]. When 35 children exposed to chemotherapy in utero were compared with 22 children
born to women with cancer who did not receive chemotherapy, there were no significant differences in cognitive skills,
academic achievement, or behavioral competence. [23]. Current practice is to avoid chemotherapy during organogenesis
in the first trimester. This study shows there may be additional benefit on fetal growth, congenital anomalies and the
incidence of preterm birth with delaying the start of chemotherapy even later into the second trimester. This is the first
analysis to examine exposures to chemotherapy in utero according to GA at the first maternal treatment, with both shortand long-term neonatal follow up data. The odds of intrauterine growth restriction increased when chemotherapy began
by 15 weeks GA. The incidence of congenital anomalies was higher when chemotherapy began prior to 16.6 weeks GA.
Odds of a spontaneous preterm birth increased significantly when chemotherapy began at 18 weeks GA. Other long-term
medical issues for the neonate, developmental delays in language or motor skills, and behavior were not related to the GA
at which chemotherapy began, nor were maternal complications of pregnancy aside from spontaneous preterm delivery.
Although there is much variation in disease and in types/classes of chemotherapy used, to our knowledge, this is the only
report to investigate neonatal and maternal consequences of chemotherapy exposures at various gestational ages,
including exposures that occurred very early in gestation.
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SUPPLEMENTARY TABLES:
Supplemental Table 1: Anomalies Listed with Details of Gestational Age at First Treatment, Age at which Anomaly
Diagnosed, Treatment if Necessary and Age of Most Recent Neonatal Evaluation by Pediatrician/Specialist
Major Birth Defect

GA
treatment

Age birth defect
diagnosed

Treatment

Age at most recent follow up
(years) Medical concerns

Hydroureter,
hydronephrosis

12.1

Suspected in utero
at 20 weeks

3.4 grade 1V vesicoureteral reflux

Hemangioma multiple

14.3

2.2 months

Antibiotics for
vesicoureteral
reflux
None

Plagiocephaly
Spina Bifida

14.4
14.7

3.4months
Suspected in utero
at 16 weeks

Helmet
Neurosurgery at
6 months: no
evidence of
tethered cord or
Chiari
malformation

Syndactyly
2 fingers
Hypospadias
Plagiocephaly

14.5

At birth

Surgery

15.1
15.1

At birth
6 months

Surgery
Helmet

Hemihypertrophy

15.3

22 months

Physical therapy

Blepharoptosis

16.6

3 weeks

None

6, Resolved by 4 months, Articulation
delay, Asthma, multiple
hyperpigmented lesions,
laryngomalasia, brief bell's palsy,
head deformity with muscle tightness

Pyloric Stenosis

16.7

1 month of age

8.6no medical issues

Cleidocranial
dysostosis

18.0

Right ureteralpelvic
junction obstruction,
hydronephrosis
Plagiocephaly

18.9

None

19.0

6 days of life,
parent has same
Autosomal
Dominant
condition,
Suspected
prenatally at
20weeks
4 months

Surgery at 6
weeks of age
None

Epibulbar dermoid
cyst

20.0

13.5 months

8.3years, right moderate
hydronephrosis, Urinary tract
infection
9, Resolved, 1 year of age, gastro
esophageal reflux
9 years of age, Articulation delay

Hydronephrosis

21.0

Thyroglossal duct cyst

22.1

Suspected
prenatally at
21weeks
28.6 months

Right ureteralpelvic
junction obstruction,
hydronephrosis

23.3

Proclins Gynecol Obstet

Suspected
prenatally at 24
weeks

Helmet
17.7 months
surgically
removed
None
Surgery at 31.6
months
Pyeloplasty at 1
month of age

6 years, Bronchospasm, Roseola
Infantum
Resolved by 10 months
7.8,
Grade II Vesicoureteral reflux, urinary
tract infections, on ditropan, motor
age 3 months behind, Reactive Airway
Disease, retinopathy, milk protein
allergy, gastroesophageal reflux
18 years
no medical issues/limitations
2.5 , Undescended testis
6.6, Resolved,9 months of age, No
medical issues
8.75Physical therapy for motor delay,
tracheomalacia, Mongolian spot

2 year, no medical issues
36months no medical issues
6, Gross motor delay,
gastroesophageal reflux, urinary
prophylaxis, Sensory issues
8/ 15

Muscular ventricular
septal defect

24.9

Congenital Scoliosis

27.1

Murmur heard age
2 months during
fever, small VSD
found,
asymptomatic
Diagnosed 4
months

No treatment

Wears Brace

5.1 years, expressive speech delay,
Otitis media with tubes placed, Gross
motor delay

Supplemental Table 2: Complications for mother at birth, at time of delivery or pediatric follow up for newborn
•

Perinatal complications for the mother during pregnancy and delivery, at birth (perinatal) or during pediatric
follow up for the newborn Gestational Age at Initiation of Chemotherapy: 12-14 weeks.

Perinatal
Complications Maternal

Gestational
Age at
Delivery
(weeks)

Perinatal Complications –
Neonatal

Pediatric Medical Conditions,
Developmental Delays or
Behavioral Issues

Preeclampsia

30.1

Apnea of prematurity, Respiratory
Distress Syndrome

IgA deficiency, phimosis, constipation,
gastroesophageal reflux

Preeclampsia

34.7

Non-ossifying fibroma of femur, low
Body Mass Index sees nutritionist

36.1

Asthma

Postpartum Depression

36.0

Placental Abruption

33.3

Clogged tear duct

38.4

Gastro esophageal reflux

Pyelonephritis, ureteral
obstruction and
Clostridium.difficile

Chorioamnionitis twins

34.0
35.3

Asthma

29.6

Eczema in 1 twin

32.1

Asthma, pedal warts

35
36.3

Proclins Gynecol Obstet

Hypoglycemia
Asthma, hydrocele
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31.1

31.6

Motor delay at 10 months

27.0

Strabismus in each twin

35.6
Anemia

Depression

38.0

Gastro esophageal reflux, eczema

37.3

Sacral dimple, surgery for spinal cyst
Ventriculomegaly noted at 16 week
fetal ultrasound, CT (computed
tomography) scan 2 months of age
showed prominence of lateral
ventricles with no other
abnormalities, no intervention
required

Attention deficit hyperactivity
disorder, educational and behavioral
delays

40.0

40.0

Seborrhea of infant

37.9

Bronchiolitis, recurrent otitis media
Torticollis, gastroesophageal reflux

37.7
38.4

Proclins Gynecol Obstet

Transient tachypnea of the
newborn

36.6

37.4

Postpartum
hemorrhage

Anemia required transfusion;
hyaline membrane disease;
hypoglycemia; apnea and
bradycardia

Gastroesophageal reflux, asthma, food
allergies, dermatitis
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•

Perinatal complications for the mother during pregnancy and delivery, at birth (perinatal) or during pediatric
follow up for the newborn Gestational Age at Initiation of Chemotherapy: 15-16 weeks.

Perinatal
Complications Maternal

Gestational Age at
Delivery

Perinatal
Complications Neonatal

36.7
37

Deep Vein Thrombosis

Gastroesophageal reflux, asthma,
contact dermatitis

36.1

Sclerosis for lymphatic
malformation in neck

33.4

Apnea and bradycardia,
weight loss

36.3

Pustular rash at birth,
resolved by 72 hours,
hyperbilirubinemia,
laryngomalacia
Lymphopenia

34.6

Gastroesophageal reflux

Bell's palsy, asthma, hyperpigmented
lesions no other criteria for
neurofibromatosis

38.6

Fine motor delay, occupational therapy,
normal by age 3 years
Articulation problems- receiving speech
therapy
Articulation issue, referred for speechresolved within 1 year
Low Body Mass Index, eczema

33.6

Asthma

36.3
39.7

36.9

•

Pediatric Medical Conditions,
Developmental Delays or
Behavioral Issues
Strabismus, hemangioma

Tracheomalacia

Perinatal complications for the mother during pregnancy and delivery, at birth (perinatal) or during pediatric
follow up for the newborn Gestational Age at Initiation of Chemotherapy: 17-18 weeks.

Perinatal
Complications
Maternal
GDM (gestational
diabetes mellitus)
Superficial vein phlebitis
GDM
Preeclampsia,
postpartum hemorrhage

Gestational Age
at Delivery

Perinatal Complications
- Neonatal

35.9
29.6
35.2
34.7
37.1
34.3

Vulvovaginitis

Hyperbilirubinemia
Respiratory distress
syndrome

Renal colic, GDM
Fractured coccyx

36.6
37.6

Hypoglycemia

Anemia, GDM,

34.1

Hypoglycemia

Proclins Gynecol Obstet

Pediatric Medical Conditions,
Developmental Delays or
Behavioral Issues

Colic, chronic benign neutropenia at 2
years of age, recurrent epistaxis.
Mild left upper lid ptosis, runs in family
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postpartum depression
Postpartum depression
when began radiation

38.9
39.0

Hashimoto’s thyroiditis, vitiligo age 7

38.7

Respiratory syncytial virus, bronchiolitis
at 16months
Vitiligo

39.1
•

Perinatal complications for the mother during pregnancy and delivery, at birth (perinatal) or during pediatric
follow up for the newborn Gestational Age at Initiation of Chemotherapy: 19-20 weeks.

Perinatal
Complications –
Maternal

Gestational Age
at Delivery

Perinatal Complications
– Neonatal

36.9
Breech, oligohydramnios

36.4

Oligohydramnios

37.4
34.6
35.6`
32.4 twins

Anemia, transfused

Chorioamnionitis
Pregnancy induced
hypertension

39.4
36.6
35.0
38.1
37.0
38.7
38.3
34.3

Each mild respiratory
distress syndrome, 1 with
oral thrush, apnea of
prematurity

Postpartum hemorrhage

•

39.3
34.4
36.9

Bronchiolitis, asthma, iron deficiency
anemia
Asthma for each twin

Mild articulation issues
Hyperbilirubinemia
Apnea of Prematurity
Hyperbilirubinemia

38.0
Postpartum depression

Pediatric Medical Conditions,
Developmental Delays or
Behavioral Issues
Asthma, Attention deficit hyperactivity
disorder
Attention deficit hyperactivity disorder
age 7, no treatment by age 10
Gastroesophageal reflux

Gastroesophageal reflux
Bronchiolitis
Gastroesophageal reflux
Gastroesophageal reflux
Gastroesophageal reflux
Failure to thrive 18mths, resolved by
34
Mild speech delay at 16 months,
resolved by 38months
Asthma

Hypoglycemia, required brief
respiratory support

38.3
40.1
34.6

Pneumonia
Vaginitis

Perinatal complications for the mother during pregnancy and delivery, at birth (perinatal) or during pediatric
follow up for the newborn Gestational Age at Initiation of Chemotherapy: 21-24 weeks.

Perinatal
Complications
- Maternal
Placental
abruption

Gestational
Age at
Delivery
28.3

Proclins Gynecol Obstet

Perinatal Complications - Neonatal
Anemia requiring transfusion

Pediatric Medical Conditions,
Developmental Delays or
Behavioral Issues
Gastroesophageal reflux
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chorioamnionitis
Anemia requiring
transfusion

33.9

Fetal Arrhythmia

40.3
Postpartum
hemorrhage
Hyperemesis
Oligohydramnios
and poor
biophysical
profile

Placenta Previa,
bleeding;
postpartum
depression
Cesarean
Section wound
cellulitis
Placental
abruption,
postpartum
depression
Postpartum
Depression,
anemia
Postpartum
Depression

38.9
36.6

Leukopenia

36

Failure to thrive

27.7

Anemia of prematurity

36.6

Neutropenia, resolved by 7 months, normal
immune system cleared by pediatric
immunologist

38.1
33.6

Placenta Previa,
uterine atony,
postpartum
hemorrhage
Postpartum
hemorrhage

Proclins Gynecol Obstet

Asthma
Sepsis, Respiratory distress syndrome,
anemia

39.0
36.0

Eczema, GERD
Hand, foot, mouth disease,
gastroesophageal reflux

39
37.9

Reactive Airway Disease

36.7
37.7
38.6

HELLP
Syndrome
Group B Strep
bacteriuria,
Gestational
diabetes

Single hemangioma,
Fine motor delay
Eczema, food allergies
Gastroesophageal reflux , sensory
issues and anxiety
Expressive and receptive language
delay, sensorineural hearing loss
Expressive speech delay,
Gastroesophageal reflux, lumbar
lordosis

1 twin Asperger’s, Tourette’s,
Obsessive Compulsive Disorder,
fraternal twin no behavioral or
developmental issues

35.3
37.4

40.9
37.3

Speech delay

40.9
38

Recurrent Otitis media
Recurrent Otitis media
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36.7
36.4
30.4

Postpartum
depression

Twins, each with apnea

36.7

36.3
•

Asthma, otitis media; mild expressive
speech delay, delay of fine motor
skills
Gastroesophageal reflux
Each twin sees vision specialist
Asthma, otitis media, childhood
obesity, fine motor and expressive
language delay

Respiratory distress syndromess

Perinatal complications for the mother during pregnancy and delivery, at birth (perinatal) or during pediatric
follow up for the newborn Gestational Age at Initiation of Chemotherapy: After 25 weeks

Perinatal
Complications Maternal

Gestational
Age at
Delivery
38.3

Perinatal Complications - Neonatal

38.0
33.6
39.0
34.9

Jaundice
Hypoglycemia

28
34.1
34.4

Retained placenta

Retained
placenta,
hemorrhage
Postpartum
hemorrhage
Postpartum
depression
Anemia requiring
transfusion at
delivery
Gastroenteritis,
Upper respiratory
Proclins Gynecol Obstet

33.9
35.1
37.3

Hypoglycemia

Respiratory distress syndrome, day 1 of life
hypoxic episode and tachypnea x 24 hrs.
prior to intubation, 2 spontaneous
pneumothoraxes, seizures prompted
Magnetic Resonance Imaging which showed
periventricular leukomalacia
Respiratory distress syndrome, anemia of
prematurity
Apnea, hypoglycemia, gastritis

Pediatric Medical Conditions,
Developmental Delays or
Behavioral Issues
Urticaria, Osgood-Schlatter disease in
knees
Gastroesophageal reflux
Developmental delay; legal blindness

Bronchiolitis
Oral motor issues & feeding issuesspeech therapy

Respiratory distress syndrome
Apnea

Speech delay, gastroesophageal reflux,
Mongolian spot and nevus

39.6
36.0
38.9
39.3

Bronchitis
Speech Delay Recurrent otitis media

36.9
33.4
35.6

Scoliosis; premature adrenarche
Eczema
Recurrent otitis media, upper
respiratory infection

38.9

Hyperbilirubinemia

Underweight
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infection
Deep vein
thrombosis,
pneumonia,
anemia requiring
transfusion at
delivery

31.0

Respiratory distress syndrome, anemia of
prematurity

33.0
33.9

Neutropenia, anemia, narcotic withdrawal
Respiratory distress syndrome

37.6

Attention deficit hyperactivity
disorder, reading support
Gastroesophageal reflux
Referred for expressive speech
therapy 18-24months, resolved by age
36months

34.3
34.6

Gestational
diabetes

35.6
37.7
37.7
38.1
36.9

Proclins Gynecol Obstet

Hypoglycemia
Gastroesophageal reflux
Recurrent otitis media

37.7
37.7

Exercise induced asthma; sleep apnea,
speech therapy
Multiple food allergies; atopic
dermatitis
Asthma
Eczema

35.4
39.7
34.7

Corneal abrasion
Single hemangioma behind knee
Speech therapy; constipation

39.3
Gestational
diabetes

Food allergies, eczema, asthma,
hemangioma on back, unilateral
hydrocele; asthma
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